Answers are grounded in this paper and cite their sources.
Featured Article: Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al., for the HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991–2002.4 Criteria for the diagnosis of gestational diabetes mellitus (GDM)5 based on association of levels of glycemia during pregnancy with subsequent maternal diabetes were first published 55 years ago (1). With adjustments for measurement of glucose in plasma rather than in whole blood and use of enzymatic methods, these criteria remain in use in the US and some other areas. Despite recognition of GDM by various professional organizations in 1979 to 1980, questions remained: (a) Were adverse outcomes attributed to GDM linked to maternal hyperglycemia or to confounding factors such as obesity, maternal age, and less socioeconomic advantage, and (b) did GDM treatment reduce adverse outcomes? The first question was addressed by the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) Study, published in the article featured here. The hypothesis was that hyperglycemia in pregnancy, less severe than diabetes, was associated with increased risk of adverse maternal, fetal, and neonatal outcomes independently related to the degree of metabolic disturbance. Eligible women at 15 sites from 9 countries underwent a 75-g, 2-h oral glucose tolerance test (OGTT) at 24 to 32 weeks' gestation, with the target being 28 weeks. Samples were drawn fasting and at 1 h and 2 h after the glucose load. Fasting, 2-h, and random plasma glucose levels at 34 to 37 weeks' gestation were analyzed in local field center laboratories to identify the need for unblinding. Aliquots of the OGTT were analyzed at the central laboratory of the HAPO Study, and these results were used in the analyses reported in the article; 25505 eligible women completed an OGTT. Participants were unblinded with glucose values outside a prespecified range, failure to complete the study usually because of delivery at another hospital, or unanticipated glucose testing for clinical reasons. A total of 23316 women completed the study. Associations of maternal fasting, 1-h, and 2-h 75-g OGTT values with primary study outcomes birth weight above the 90th percentile for gestational age, primary cesarean delivery, clinically diagnosed neonatal hypoglycemia, and cord-blood serum C-peptide above the 90th percentile were continuous. There were no obvious thresholds at which risks increased. Significant associations were also observed for secondary outcomes, although these tended to be weaker. Successful completion of the HAPO Study required overcoming numerous challenges. In many of the clinical centers, participants were agreeing to a blinded research metabolic study instead of what was routine, well-established clinical practice. To achieve equivalence of glucose-based entry requirements, measurement of glucose in multiple field laboratories required rigorous standardization. Accurate measurements required integration of local and central laboratory functions both before and throughout the study. Before the study, all field laboratories were aligned with the central laboratory; during the study, external quality assessment of all laboratories (field and central) was performed at 2-weekly intervals to maintain accuracy and identify possible analytical drift (2); by this means, recruitment bias—based on glucose measurement at 15 separate field centers—was avoided. The standard logistics of safely transporting samples in dry ice for analysis from 14 sites to the central laboratory in Belfast, UK, some at great distances (e.g., from Australia, Hong Kong, and the US), were challenged during the severe acute respiratory syndrome epidemic that affected 2 HAPO sites and by new, stricter transporting regulations introduced following the September 11, 2001 bombings in the US. The data from the HAPO Study became the primary basis for the development of pregnancy outcome-based GDM criteria by the International Association of Diabetic Pregnancy Study Groups in 2010 (3), which have been incorporated into practice in many, but not all, parts of the world. Because of the change from requiring 1 instead of 2 increased glucose values, use of these new criteria has increased the prevalence of GDM, consistent with the worldwide epidemic of obesity and type 2 diabetes. gestational diabetes mellitus Hyperglycemia and Adverse Pregnancy Outcomes (Study) oral glucose tolerance test.
No takes yet. Share an insight, caveat, or question.
Metzger et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: